IGF-binding proteins secreted by cancer-associated fibroblasts induce context-dependent drug sensitization of lung cancer cells

• Published in: Science signaling Vol. 15; no. 747; p. eabj5879
• Main Authors: Remsing Rix, Lily L, Sumi, Natalia J, Hu, Qianqian, Desai, Bina, Bryant, Annamarie T, Li, Xueli, Welsh, Eric A, Fang, Bin, Kinose, Fumi, Kuenzi, Brent M, Chen, Y Ann, Antonia, Scott J, Lovly, Christine M, Koomen, John M, Haura, Eric B, Marusyk, Andriy, Rix, Uwe
• Format: Journal Article
• Language: English
• Published: United States 16-08-2022
• Subjects: Animals; Cancer-Associated Fibroblasts - metabolism; Cell Line, Tumor; Culture Media, Conditioned - pharmacology; ErbB Receptors - metabolism; Fibroblasts - metabolism; Insulin-Like Growth Factor Binding Proteins - metabolism; Insulin-Like Growth Factor Binding Proteins - pharmacology; Insulin-Like Growth Factor Binding Proteins - therapeutic use; Lung - metabolism; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Lung Neoplasms - pathology; Mice; Tumor Microenvironment
• ISSN: 1937-9145
• DOI: 10.1126/scisignal.abj5879

Cancer-associated fibroblasts (CAFs) in the tumor microenvironment are often linked to drug resistance. Here, we found that coculture with CAFs or culture in CAF-conditioned medium unexpectedly induced drug sensitivity in certain lung cancer cell lines. Gene expression and secretome analyses of CAFs and normal lung-associated fibroblasts (NAFs) revealed differential abundance of insulin-like growth factors (IGFs) and IGF-binding proteins (IGFBPs), which promoted or inhibited, respectively, signaling by the receptor IGF1R and the kinase FAK. Similar drug sensitization was seen in gefitinib-resistant,
-mutant PC9GR lung cancer cells treated with recombinant IGFBPs. Conversely, drug sensitivity was decreased by recombinant IGFs or conditioned medium from CAFs in which
or
was silenced. Phosphoproteomics and receptor tyrosine kinase (RTK) array analyses indicated that exposure of PC9GR cells to CAF-conditioned medium also inhibited compensatory IGF1R and FAK signaling induced by the EGFR inhibitor osimertinib. Combined small-molecule inhibition of IGF1R and FAK phenocopied the CAF-mediated effects in culture and increased the antitumor effect of osimertinib in mice. Cells that were osimertinib resistant and had
amplification or showed epithelial-to-mesenchymal transition also displayed residual sensitivity to IGFBPs. Thus, CAFs promote or reduce drug resistance in a context-dependent manner, and deciphering the relationship between the differential content of CAF secretomes and the signaling dependencies of the tumor may reveal effective combination treatment strategies.